Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AssigneeThe Regents of the University of Carlifornia
InventorsJames D. Marks, Peter Amersdorfer
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Claims118
An isolated antibody that specifically binds to an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1, wherein said antibody binds to and neutralizes botulinum neurotoxin type A (BoNT/A).
An isolated anti-botulinum neurotoxin type A (anti-BoNT/A) antibody, said antibody comprising a variable heavy (VH) complementarity determining region (CDR) listed in Table 4, Table 9, or Table 11, and wherein said antibody specifically binds to and neutralizes a botulinum neurotoxin type A.
A method of neutralizing a botulinum neurotoxin type A (BoNT/A), said method comprising contacting said botulinum neurotoxin type A with a first anti-botulinum neurotoxin type A (anti-BoNT/A) antibody, said antibody comprising a variable heavy (VH) complementarity determining region (CDR) listed in Table 4, Table 9, or Table 11 said antibody having a specificity and affinity such that it specifically binds to binds to and neutralizes said botulinum neurotoxin type A.
A polypeptide comprising botulinum neurotoxin type A (BoNT/A) neutralizing epitope, said neutralizing epitope comprising an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1, wherein said polypeptide is not a full-length botulinum neurotoxin Hc fragment.
A method of making a botulinum neurotoxin type A antibody (anti-BoNT/A) that neutralizes BoNT/A, said method comprising:
- contacting a plurality of antibodies with a an epitope specifically bound by an antibody expressed by a clone selected from the group consisting of clone S25, clone C25, clone C39, clone 1C6, clone 3D12, clone B4, clone 1F3, clone huC25, clone Ar1, clone Ar2, clone WR1(V), clone WR1(T), clone 3-1, clone 3-8, clone 3-10, and clone ING1;
- and
- isolating an antibody that specifically binds to said epitope.
A composition comprising a plurality of anti-botulinum neurotoxin antibodies, wherein each antibody is specific for a different epitope of a botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality.
A method of neutralizing a botulinum neurotoxin, said method comprising contacting said neurotoxin with a plurality of anti-botulinum neurotoxin antibodies, wherein each antibody is specific for a different epitope of said botulinum neurotoxin, and wherein said combination of antibodies shows greater toxin neutralization than the single antibodies comprising said plurality.
Dependencies are inferred from the claim text.